TABLE 3.
Evidence against the use of HCQ | |||||
---|---|---|---|---|---|
Study | Study type | Country | Population size | Results | Ref |
A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) | Single-center RCT | China | 30 | No significant prognostic difference was noted between the HCQ-treated group and the control group.Comparable adverse events were experienced by each group. Studied outcomes included: • Time to negative conversion • time for body temperature normalization • radiological progression• adverse events experienced by both groups | (Chen J. et al., 2020) |
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial | Multi-center RCT | China | 150 | No significant prognostic difference was noted between the HCQ-treated group and the control group. More adverse events were observed in the treated group.Studied outcomes included: • Time to negative conversion • adverse events experienced by both groups | (Tang et al., 2020) |
Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state | Multi-center retrospective cohort study | United States, New York | 1,438 | There was no significant improvement in mortality rate in hospitalized COVID-19 patients treated with HCQ, azithromycin or HCQ + azithromycin. Studied outcomes included: • In-hospital mortality • incidence of fatal cardiac events | (Rosenberg et al., 2020) |
Observational study of hydroxychloroquine in hospitalized patients with Covid-19 | Single-center, observational study | United States, New York | 1,446 | The use of HCQ had no significant effect on clinical outcomes and in-hospital mortality.Studied outcomes included: • Clinical worsening (denoted by the need for intubation) • death | (Geleris et al., 2020) |